How much benefit Bisantrene can bring cancer patients. When you look at how many patients are treated with anthracyclines every year and how many are permanently harmed from the treatment, the potential of bisantrene to help millions of people is breathtaking. Add in FTO and you have something amazing.
On a personal level how contingent on me all this turned out to be. If I hadn’t decided to do DD research on all the listed biotechs and hadn’t decided to contact Peter Malloy (the CEO of Race at the time), Bisantrene would have been lost forever. Race was very close to running out of money, dropping Bisantrene, and becoming just another biotech shell.
Ann: Zantrene AML trial in Israel advances to Phase 2, page-134
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.020(1.31%) |
Mkt cap ! $267.5M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.57 | $1.55 | $1.987K | 1.274K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6040 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.56 | 1462 | 2 |
View Market Depth
| Last trade - 10.53am 17/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |